Global Sunitinib Malate Market Set to Surge, Projected to Reach $278.54 Million by 2032

DUBLIN, Aug. 30, 2023 /PRNewswire/ -- The "Sunitinib Malate Market Share, Size, Trends, Industry Analysis Report, By Application, By Region, Segment Forecast, 2023-2032" report has been added to  ResearchAndMarkets.com's offering.

The global sunitinib malate market is on the brink of significant expansion, with a projected value of USD 278.54 million by 2032, as outlined in a comprehensive new study. The report delves into current market dynamics and provides a meticulous analysis of future growth prospects.

Impetus from FDA Approvals and Cancer Research Advancements

Investor confidence in the pharmaceutical industry has been buoyed by the FDA's approval of sunitinib malate and other targeted cancer therapies. The year 2022 witnessed substantial breakthroughs in cancer research. The U.S. Food and Drug Administration (FDA) greenlit 40 drugs for oncology indications, including 12 entirely new molecules that had never been utilized in human treatments before. This surge of approvals could catalyze increased investments in research and development, leading to the discovery of novel cancer treatments and further propelling market expansion.

Global Cancer Prevalence Powers Sunitinib Demand

Cancer remains a leading cause of mortality worldwide, and it significantly underpins the growth trajectory of the sunitinib market. Sunitinib Malate, a vital treatment for specific cancers such as renal cell carcinoma and gastrointestinal stromal tumors, is witnessing growing demand due to the escalating incidence of cancer globally. According to the World Health Organization (WHO), an estimated 19.3 million new cases of cancer and 10 million cancer-related deaths were reported in 2020. The increasing prevalence of cancer is anticipated to persist, driven by factors such as population aging, changing lifestyles, and environmental influences.

Surge in Healthcare Expenditure Boosts Market Growth

The ascending healthcare expenditure in both developed and developing nations is a formidable driver for the sunitinib malate market's growth. Contributing factors include an aging population, higher prevalence of chronic diseases, and governmental initiatives aimed at enhancing cancer care. OECD Health Data 2022, updated in November 2022, suggests that health spending in a group of 20 countries increased by an average of 6% in 2021, underlining the robust growth trajectory.

Innovative Cancer Treatments Fuel Market Momentum

The emergence of innovative cancer treatments, including targeted therapies like sunitinib malate, is a key driving force for market expansion. These therapies offer enhanced efficacy and reduced side effects compared to traditional chemotherapy methods. The American Association for Cancer Research notes that due to advancements in cancer research and treatment, there will be more cancer survivors in the United States than the predicted 18 million by early 2022. Despite these strides, the battle to mitigate the burden of preventable cancer continues, demanding ongoing advancements in disease detection and treatment.

Market Highlights

• The Pancreatic Neuroendocrine Tumor segment is predicted to exhibit a higher growth rate due to the rising incidence of PNET.
• North America is expected to experience substantial growth and capture a larger revenue share, driven by a high prevalence of cancer.
• Europe is anticipated to secure the second-largest revenue share during the study period, fueled by a growing elderly population.

Key Market Players

The global players shaping the sunitinib malate landscape include Pfizer, Top Care Pharmacy, J&K Scientific, Targetmol, Active Biotech, Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Dendreon, Endo International & Ferring Pharmaceuticals.

For more information about this report visit https://www.researchandmarkets.com/r/z0l589

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets